BIND-014 (docetaxel nanoparticles for injectable suspension) is being studied in patients with v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog mutation positive or NSCLC who have progressed after treatment of one prior platinum-containing chemotherapy regimen. This evidence concerns the gene KRAS and non-small cell lung carcinoma.